Nephrol Dial Transplant (2003) 18: 1909-1916
© 2003 European Renal Association-European Dialysis and Transplant Association
The long-term effect of switching from cyclosporin A to mycophenolate mofetil in chronic renal graft dysfunction compared with conventional management
1 Nephrology Unit and 2 Anatomopathology Unit, 94270 Le Kremlin-Bicêtre and 3 INSERM U542, 94800 Villejuif, France
Correspondence and offprint requests to: Antoine Dürrbach, Nephrology Unit, University Hospital of Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin Bicêtre, France. Email: antoine.durrbach{at}bct.ap-hop-paris.fr
Background. To overcome toxicity of calcineurin inhibitors, recent trials have proposed substituting cyclosporin (CysA) with mycophenolate mofetil (MMF). No data concerning the long-term side effects and long-term renal outcome of this strategy have been published.
Methods. We retrospectively compared 39 renal transplant patients with chronic graft dysfunction who were subjected to CysA to MMF substitution (group 1) with 39 matched renal transplant patients who were continued on conventional management (group 2). The mean serum creatinine and the slope of deterioration of renal function before the date of the therapeutic intervention (T0) were similar in both groups. Follow-up in both groups was 76 ± 42 months before T0 and 44 ± 11 months after T0.
Results. In group 1, conversion was associated with a decrease of mean serum creatinine concentrations from 192 to 172 µmol/l at 1 year (P = 0.004) and 159 µmol/l at 3 years (P < 0.003) after T0, whereas it remained unchanged in group 2. The systolic blood pressure decreased in group 1 from 155 mmHg before T0 to 145 mmHg at 1 year (P < 0.01) and 133 mmHg at 3 years (P < 0.001) without any increase of the antihypertensive drug, whereas it did not change in group 2. Lipid profile tended to improve in group 1 after T0 and was unchanged in group 2. None of the patients in group 1 developed acute rejection after T0, whereas two acute rejections occurred in group 2. Graft survival, however, was similar in both groups. In group 1, several side effects occurred related to MMF treatment, and led to its discontinuation in two cases and the reduction of its dose for 18 patients (64%).
Conclusion. CysA/MMF substitution improves renal function and blood pressure in chronic allograft dysfunction when compared with conventional management. However, CysA/MMF substitution is associated with a high rate of MMF-related side effects, requiring modulation of its dose.
Keywords: cyclosporin A; graft dysfunction; mycophenolate mofetil; substitution
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Hanvesakul, C. Kubal, S. Jham, E. Sarkar, K. Eardley, D. Adu, and P. Cockwell Increased incidence of infections following the late introduction of mycophenolate mofetil in renal transplant recipients Nephrol. Dial. Transplant., December 1, 2008; 23(12): 4049 - 4053. [Abstract] [Full Text] [PDF]
|
|